Endostar inhibits hypoxia-induced cell proliferation and migration via the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in vitro

Lin,Kana; Ye,Panpan; Liu,Jian; He,Fengying; Xu,Wen

doi:10.3892/mmr.2014.3131

Endostar inhibits hypoxia-induced cell proliferation and migration via the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in vitro

Authors:
- Kana Lin
- Panpan Ye
- Jian Liu
- Fengying He
- Wen Xu
View Affiliations

Affiliations: Department of Clinical Pharmacology, The Second Affiliated Hospital (Binjiang Branch), School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310052, P.R. China, Eye Center, The Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
Published online on: December 23, 2014 https://doi.org/10.3892/mmr.2014.3131
Pages: 3780-3785

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endostar, a recombinant human endostatin, is recognized as one of the most effective angiogenesis inhibitors. The angiogenesis inhibitory effects of Endostar suggest a possible beneficial role of Endostar in choroidal neovascularization (CNV), which is predominantly induced by hypoxia. In our previous study, it was reported that Endostar may inhibit the proliferation and migration of RF/6A choroid‑retinal endothelial cells. However, the inhibitory effect of Endostar on hypoxia‑induced cell proliferation and migration in RF/6A cells has not yet been elucidated. Therefore, the present study investigated the effect of Endostar on hypoxia‑induced cell proliferation and migration in RF/6A cells and the possible mechanisms underlying this effect. Under chemical hypoxia conditions, cell viability was increased to 114.9±10.1 and 123.6±9.6% in cells treated with 100 and 200 µm CoCl2, respectively, compared with the control (P<0.01). Pretreatment with 10‑100 µg/ml Endostar significantly inhibited CoCl2‑induced cell proliferation (P<0.05), and pre‑treatment with 10 µg/ml Endostar for 24, 48 and 96 h attenuated CoCl2‑promoted cell migration by 60.5, 48.3 and 39.6%, respectively, compared with the control (P<0.001). In addition, pretreatment with 10 µg/ml Endostar reversed the cell cycle arrest at S phase and the increased expression of hypoxia‑inducible factor‑1α (HIF‑1α) and vascular endothelial growth factor (VEGF) mRNA in RF/6A cells treated with 200 µM CoCl2. These data indicate that Endostar inhibited CoCl2‑induced hypoxic proliferation and migration, and limited cell cycle progression in vitro possibly through the HIF‑1α/VEGF pathway.

View Figures

View References

1	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
2	Ambati J, Ambati BK, Yoo SH, Ianchulev S and Adamis AP: Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 48:257–293. 2003. View Article : Google Scholar : PubMed/NCBI
3	Friedman DS, O’Colmain BJ, Munoz B, et al: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 122:564–572. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bhutto I and Lutty G: Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med. 33:295–317. 2012. View Article : Google Scholar : PubMed/NCBI
5	Xie P, Zhang W, Yuan S, et al: Suppression of experimental choroidal neovascularization by curcumin in mice. PLoS One. 7:e533292012. View Article : Google Scholar
6	Yang XM, Wang YS, Zhang J, et al: Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci. 50:1873–1879. 2009. View Article : Google Scholar
7	Dong X, Wang YS, Dou GR, et al: Influence of DII4 via HIF-1alpha-VEGF signaling on the angiogenesis of choroidal neovascularization under hypoxic conditions. PLoS One. 6:e184812011. View Article : Google Scholar
8	Kang HM and Koh HJ: Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. Am J Ophthalmol. 155:713–719. 2013. View Article : Google Scholar
9	Kim YM, Jang JW, Lee OH, et al: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60:5410–5413. 2000.PubMed/NCBI
10	Abdollahi A, Hlatky L and Huber PE: Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat. 8:59–74. 2005. View Article : Google Scholar : PubMed/NCBI
11	Mori K, Ando A, Gehlbach P, et al: Campochiaro PA. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol. 159:313–320. 2001. View Article : Google Scholar : PubMed/NCBI
12	Tatar O, Shinoda K, Kaiserling E, et al: Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol. 126:193–199. 2008. View Article : Google Scholar : PubMed/NCBI
13	Xu W, Ye P, Li Z, Shi J, Wang W and Yao K: Endostar, a recently introduced recombinant human endostatin, inhibits proliferation and migration through regulating growth factors, adhesion factors and inflammatory mediators in choroid-retinal endothelial cells. Mol Biol. 44:664–670. 2010. View Article : Google Scholar
14	Neely KA and Gardner TW: Ocular neovascularization: clarifying complex interactions. Am J Pathol. 153:665–670. 1998. View Article : Google Scholar : PubMed/NCBI
15	Hay WW Jr and Bell EF: Oxygen therapy, oxygen toxicity, and the STOP-ROP trial. Pediatrics. 105:424–425. 2000. View Article : Google Scholar : PubMed/NCBI
16	Plum SM, Vu HA, Mercer B, Fogler WE and Fortier AH: Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction. Immunopharmacol Immunotoxicol. 26:29–41. 2004. View Article : Google Scholar : PubMed/NCBI
17	Chen Y, Li XX, Xing NZ and Cao XG: Quercetin inhibits choroidal and retinal angiogenesis in vitro. Graefes Arch Clin Exp Ophthalmol. 246:373–378. 2008. View Article : Google Scholar
18	Ling Y, Yang Y, Lu N, et al: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
19	Jiang LP, Zou C, Yuan X, Luo W, Wen Y and Chen Y: N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem. 54:113–120. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lu N, Ling Y, Gao Y, et al: Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med. 233:1013–1020. 2008. View Article : Google Scholar
21	Wen QL, Meng MB, Yang B, et al: Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci. 100:1510–1519. 2009. View Article : Google Scholar : PubMed/NCBI
22	Bong R, Yang S, Li W, Zhang W and Ming Z: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 10:1702012. View Article : Google Scholar
23	Covello KL, Simon MC and Keith B: Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res. 65:2277–2286. 2005. View Article : Google Scholar : PubMed/NCBI
24	Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med. 54:17–28. 2003. View Article : Google Scholar
25	Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 88:1474–1480. 2000.PubMed/NCBI
26	Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA and Semenza GL: Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 93:1074–1081. 2003. View Article : Google Scholar : PubMed/NCBI
27	Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, Thompson HW and Bazan NG: Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci. 44:4163–4170. 2003. View Article : Google Scholar : PubMed/NCBI
28	Berglin L, Sarman S, van der Ploeg I, et al: Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci. 44:403–408. 2003. View Article : Google Scholar
29	Haas TL: Endothelial cell regulation of matrix metalloproteinases. Can J Physiol Pharmacol. 83:1–7. 2005. View Article : Google Scholar : PubMed/NCBI
30	Moses MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 15:S180–S189. 1997. View Article : Google Scholar
31	Jia Y, Liu M, Cao L, et al: Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol. 32:316–324. 2011.PubMed/NCBI
32	Zhang L, Ge W, Hu K, et al: Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep. 39:89–95. 2012. View Article : Google Scholar